Clinical Trials Browser

Terminated × bivatuzumab mertansine × Clear all

NCT02254031 2023-10-24

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT02254044 2014-10-01

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Phase 1 Terminated

Carcinoma, Squamous Cell